ReviewMedicine2026
Emerging biomarkers for early detection of aplastic anemia in HIV: A narrative review.
Review in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aplastic anemia (AA) in human immunodeficiency virus (HIV)-infected individuals is a complex condition that poses significant diagnostic and therapeutic challenges due to its overlap with HIV-related immune dysregulation. Early detection of AA is crucial for effective management and improved patient outcomes. Recent advances in biomarker research have identified several promising candidates that could facilitate earlier diagnosis and personalized treatment strategies. This review focuses on emerging biomarkers, including hematologic, immunologic, and molecular markers, which hold potential for the early detection of AA in HIV-infected patients. Hematologic biomarkers, such as reticulocyte count and bone marrow biopsy findings, provide initial insights into bone marrow dysfunction but may lack specificity. Immunologic biomarkers, including cytokine profiles and T-cell subsets, reflect the immune system's role in AA pathogenesis and offer potential for earlier detection through assessment of inflammation and immune dysregulation. Additionally, molecular biomarkers, such as gene expression profiles and microRNAs, provide a deeper understanding of the underlying disease mechanisms and may enable more precise diagnosis and monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.